Page 39 - Read Online
P. 39

through mammalian target of rapamycin signal cascade.  PLoS One   19.  Yasuda S,  Arii S, Mori  A, Isobe N,  Yang  W, Oe H, Fujimoto  A,
               2015;10:e0122373.                                 Yonenaga  Y, Sakashita H, Imamura M. Hexokinase II and  VEGF
           17.  Bannach P, Klimek F, Mayer D. Early bioenergetic changes in   expression in liver tumors: correlation with hypoxia-inducible factor 1
               hepatocarcinogenesis: preneoplastic phenotypes mimic responses to   alpha and its significance. J Hepatol 2004;40:117-23.
               insulin and thyroid hormone. J Bioenerg Biomembr 1997;29:303-13.  20.  Guzman G, Chennuri R, Chan A, Rea B, Quintana A, Patel R, Xu PZ, Xie
           18.  Klimek F, Bannasch P. Isoenzyme shift from glucokinase to hexokinase   H, Hay N. Evidence for heightened hexokinase II immunoexpression
               is not an early but a late event in hepatocarcinogenesis. Carcinogenesis   in hepatocyte dysplasia and hepatocellular carcinoma.  Dig Dis Sci
               1993;14:1857-61.                                  2015;60:420-6.













































































            30                                                   Hepatoma Research | Volume 2 | Issue 1 | January 15, 2016
   34   35   36   37   38   39   40   41   42   43   44